Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
FOCUS The Journal of Lifelong Learning in Psychiatry April 1, 2022 Jennifer B. Dwyer, Angeli Landeros‐Weisenberger, Jessica A. Johnson et al. 51 citations
A single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) significantly reduced depressive symptoms in adolescents with major depressive disorder 24 hours later compared with the active placebo midazolam. The treatment effects appeared to persist for 14 days on one depression scale but not another. A greater proportion of participants responded to ketamine during the first three days after infusion (76%) compared with midazolam (35%). Ketamine caused transient dissociative symptoms but no serious adverse events.